S Ananth Karumanchi

List of Publications by Year
in descending order

286 papers	37,347 citations	3515 90 h-index	3173 186 g-index
292 all docs	292 docs citations	292 times ranked	25579 citing authors

#	Article	IF	Citations
1	Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. American Journal of Obstetrics and Gynecology, 2022, 226, S1019-S1034.	0.7	120
2	The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension, 2022, 27, 148-169.	0.6	189
3	Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertension, 2022, 27, 42-50.	0.6	55
4	Indoxyl sulfate in uremia: an old idea with updated concepts. Journal of Clinical Investigation, 2022, 132, .	3.9	11
5	Angiogenesis and Preeclampsia. , 2022, , 165-185.		0
6	Risk-Factor Based Lead Screening and Correlation with Blood Lead Levels in Pregnancy. Maternal and Child Health Journal, 2022, 26, 185-192.	0.7	1
7	Cell-free plasma RNA signatures as a surrogate biomarker of pregnancy health. Med, 2022, 3, 90-92.	2.2	0
8	Discovery of antiangiogenic factors in the pathogenesis of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 226, S1035-S1036.e5.	0.7	4
9	Cardiovascular and hemodynamic consequences of recombinant placental growth factor administration in Guinea pigs. Hypertension in Pregnancy, 2022, 41, 99-106.	0.5	1
10	Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series. American Journal of Reproductive Immunology, 2022, 88, e13559.	1.2	9
11	Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1. Molecular Therapy - Nucleic Acids, 2022, 29, 135-149.	2.3	15
12	Animal Models of Cardiovascular Complications of Pregnancy. Circulation Research, 2022, 130, 1763-1779.	2.0	10
13	Risk of preâ€eclampsia in patients with a maternal genetic predisposition to common medical conditions: a caseâ€“control study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 55-65.	1.1	19
14	Low Prenatal Vitamin D Metabolite Ratio and Subsequent Postpartum Depression Risk. Journal of Women's Health, 2021, 30, 113-120.	1.5	6
15	Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy. Human Immunology, 2021, 82, 362-370.	1.2	27
16	Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease. Pregnancy Hypertension, 2021, 24, 58-64.	0.6	12
17	Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay. PLoS ONE, 2021, 16, e0254158.	1.1	5
18	An ACE inhibitor reduces bactericidal activity of human neutrophils in vitro and impairs mouse neutrophil activity in vivo. Science Translational Medicine, 2021, 13, .	5.8	20

#	Article	IF	Citations
19	Normalization of wall shear stress as a physiological mechanism for regulating maternal uterine artery expansive remodeling during pregnancy. FASEB BioAdvances, 2021, 3, 702-708.	1.3	3
20	IL-6 Inhibition Reduces Neuronal Injury in a Murine Model of Ventilator-induced Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 403-412.	1.4	24
21	Is Prolonging Gestation in Preeclampsia For Better or Worse in Preventing Cardiovascular Disease?. Hypertension, 2021, 78, 1395-1397.	1.3	0
22	Interleukin-6 mediates delirium-like phenotypes in a murine model of urinary tract infection. Journal of Neuroinflammation, 2021, 18, 247.	3.1	19
23	Insights Into the Role of Tetrahydrobiopterin Deficiency in the Pathogenesis of Gestational Hypertension. Hypertension, 2021, 78, 1885-1887.	1.3	0
24	Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia. Hypertension, 2020, 76, 875-883.	1.3	20
25	Standardising definitions for the pre-eclampsia core outcome set: A consensus development study. Pregnancy Hypertension, 2020, 21, 208-217.	0.6	9
26	A mouse model of placenta accreta spectrum. Placenta, 2020, 99, 8-15.	0.7	9
27	Sexually Dimorphic Crosstalk at the Maternal-Fetal Interface. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4831-e4847.	1.8	48
28	Lead exposure and association with angiogenic factors and hypertensive disorders of pregnancy. Pregnancy Hypertension, 2020, 22, 93-98.	0.6	3
29	Aspirin to Prevent Preterm Preeclampsia. Hypertension, 2020, 75, 941-942.	1.3	1
30	Immune cell infiltrate at the utero-placental interface is altered in placenta accreta spectrum disorders. Archives of Gynecology and Obstetrics, 2020, 301, 499-507.	0.8	12
31	Placenta accreta spectrum: biomarker discovery using plasma proteomics. American Journal of Obstetrics and Gynecology, 2020, 223, 433.e1-433.e14.	0.7	41
32	Serum Angiopoietinâ€2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology, 2019, 69, 729-741.	3.6	26
33	A Step-Wedge in the Biochemical Diagnosis of Preeclampsia. Clinical Chemistry, 2019, 65, 1348-1349.	1.5	0
34	Oral regimen management of acute hypertension in pregnancy. Lancet, The, 2019, 394, 981-982.	6.3	0
35	Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertension in Pregnancy, 2019, 38, 193-199.	0.5	31
36	Risk of ischemic placental disease is increased following in vitro fertilization with oocyte donation: a retrospective cohort study. Journal of Assisted Reproduction and Genetics, 2019, 36, 1917-1926.	1.2	19

#	Article	IF	Citations
37	Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD. Kidney International Reports, 2019, 4, 1735-1741.	0.4	4
38	A top priority in pre-eclampsia research: development of a reliable and inexpensive urinary screening test. The Lancet Global Health, 2019, 7, e1312-e1313.	2.9	7
39	Research Recommendations From the National Institutes of Health Workshop on Predicting, Preventing, and Treating Preeclampsia. Hypertension, 2019, 73, 757-766.	1.3	38
40	Vitamin Dâ€"Binding Protein Deficiency and Homozygous Deletion of the GC Gene. New England Journal of Medicine, 2019, 380, 2582-2587.	13.9	4
41	Failure in Physiologic Flexibility: Adverse Pregnancy Outcomes in Women with Reduced Renal Reserve. American Journal of Nephrology, 2019, 49, 397-399.	1.4	0
42	Solving Baroreceptor Mystery: Role of PIEZO Ion Channels. Journal of the American Society of Nephrology: JASN, 2019, 30, 911-913.	3.0	14
43	Preeclampsia. Circulation Research, 2019, 124, 1094-1112.	2.0	1,019
44	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology, 2019, 15, 275-289.	4.1	609
45	Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. Nature, 2019, 565, 96-100.	13.7	148
46	AP39, a Modulator of Mitochondrial Bioenergetics, Reduces Antiangiogenic Response and Oxidative Stress in Hypoxia-Exposed Trophoblasts. American Journal of Pathology, 2019, 189, 104-114.	1.9	50
47	Smooth Muscle Cellâ€"Mineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging. Hypertension, 2018, 71, 609-621.	1.3	60
48	Metabolic and Hypertensive Complications of Pregnancy in Women with Nephrolithiasis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 612-619.	2.2	16
49	Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Research, 2018, 46, 2185-2196.	6.5	125
50	Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. American Journal of Obstetrics and Gynecology, 2018, 218, 211-218.	0.7	66
51	Inadequate safety reporting in preâ€eclampsia trials: a systematic evaluation. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 795-803.	1.1	22
52	Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis. Obstetrics and Gynecology, 2018, 131, 63-69.	1.2	15
53	RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nature Biotechnology, 2018, 36, 1164-1173.	9.4	126
54	Complement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease. American Journal of Pathology, 2018, 188, 2147-2154.	1.9	30

#	Article	IF	Citations
55	Cerebrospinal Fluid Protein Changes in Preeclampsia. Hypertension, 2018, 72, 219-226.	1.3	25
56	Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertension, 2018, 13, 100-106.	0.6	43
57	Gene-Centric Analysis of Preeclampsia Identifies Maternal Association at PLEKHG1. Hypertension, 2018, 72, 408-416.	1.3	46
58	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFÎ²1 Axis. Clinical Cancer Research, 2018, 24, 6078-6097.	3.2	43
59	Hypertensive Disorders of Pregnancy. Hypertension, 2018, 72, 24-43.	1.3	1,200
60	Risk of Preeclampsia and Pregnancy Complications in Women With a History of Acute Kidney Injury. Hypertension, 2018, 72, 451-459.	1.3	31
61	Relationship between hypoxia and downstream pathogenic pathways in preeclampsia. Hypertension in Pregnancy, 2017, 36, 145-150.	0.5	39
62	High Glycated Albumin and Mortality in Persons with Diabetes Mellitus on Hemodialysis. Clinical Chemistry, 2017, 63, 477-485.	1.5	44
63	Offspring Cardiovascular Disease in Preeclampsia. Hypertension, 2017, 69, 589-590.	1.3	5
64	Placental soluble fms-like tyrosine kinase expression in small for gestational age infants and risk for adverse outcomes. Placenta, 2017, 52, 10-16.	0.7	14
65	Pregnancy Outcomes after Clinical Recovery from AKI. Journal of the American Society of Nephrology: JASN, 2017, 28, 1566-1574.	3.0	55
66	FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Scientific Reports, 2017, 7, 12139.	1.6	38
67	Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) and Risk of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. World Neurosurgery, 2017, 108, 84-89.	0.7	5
68	Identification of Novel Non-secosteroidal Vitamin D Receptor Agonists with Potent Cardioprotective Effects andÂï»¿ï»¿devoid of Hypercalcemia. Scientific Reports, 2017, 7, 8427.	1.6	10
69	Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. Seminars in Nephrology, 2017, 37, 386-397.	0.6	166
70	Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation. Archives of Gynecology and Obstetrics, 2017, 296, 257-262.	0.8	21
71	Acute homeostatic changes following Vitamin D2 supplementation. Journal of the Endocrine Society, 2017, 1, 1135-1149.	0.1	6
72	The pathology of eclampsia: An autopsy series. Hypertension in Pregnancy, 2017, 36, 259-268.	0.5	31

#	Article	IF	Citations
73	Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E. Oncotarget, 2017, 8, 84743-84760.	0.8	40
74	Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. Journal of Clinical Investigation, 2016, 126, 2561-2574.	3.9	111
75	Reduction of carbamylated albumin by extended hemodialysis. Hemodialysis International, 2016, 20, 510-521.	0.4	9
76	KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertension in Pregnancy, 2016, 35, 330-345.	0.5	34
77	Angiogenic Factors in Preeclampsia. Hypertension, 2016, 67, 1072-1079.	1.3	121
78	Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension, 2016, 67, 1263-1272.	1.3	89
79	Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension, 2016, 67, 1273-1280.	1.3	57
80	A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertension, 2016, 6, 274-278.	0.6	48
81	Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury. Digestive Diseases and Sciences, 2016, 61, 3609-3620.	1.1	8
82	Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertension, 2016, 6, 333-339.	0.6	9
83	Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1809-1816.	2.2	23
84	Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13450-13455.	3.3	50
85	A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancerÂscreening trial. Cancer Causes and Control, 2016, 27, 1009-1017.	0.8	4
86	Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. Pregnancy Hypertension, 2016, 6, 313-319.	0.6	41
87	National Heart, Lung, and Blood Institute Working Group Report on Salt in Human Health and Sickness. Hypertension, 2016, 68, 281-288.	1.3	48
88	Revisiting decidual vasculopathy. Placenta, 2016, 42, 37-43.	0.7	48
89	Toward a Better Diagnosis for Preeclampsia. Clinical Chemistry, 2016, 62, 913-915.	1.5	8
90	Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study. American Journal of Obstetrics and Gynecology, 2016, 215, 594.e1-594.e11.	0.7	20

#	Article	IF	Citations
91	ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitorâ€“Induced Thrombotic Microangiopathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 120-131.	3.0	11
92	PGC1Î± drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature, 2016, 531, 528-532.	13.7	395
93	Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation, 2016, 133, 518-536.	1.6	149
94	Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. Hypertension, 2016, 67, 740-747.	1.3	118
95	Sequential plasma angiogenic factors levels in women with suspected preeclampsia. American Journal of Obstetrics and Gynecology, 2016, 215, 89.e1-89.e10.	0.7	56
96	Preeclampsia and Pregnancy-Related Hypertensive Disorders. Hypertension, 2016, 67, 238-242.	1.3	76
97	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. Journal of the American Society of Nephrology: JASN, 2016, 27, 903-913.	3.0	213
98	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. American Journal of Obstetrics and Gynecology, 2016, 214, 108.e1-108.e14.	0.7	122
99	Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension. Pulmonary Circulation, 2016, 6, 498-507.	0.8	15
100	Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Patients with Obstructive Sleep Apnea. PLoS ONE, 2016, 11, e0154503.	1.1	4
101	Induced Human Decidual NK-Like Cells Improve Utero-Placental Perfusion in Mice. PLoS ONE, 2016, 11, e0164353.	1.1	20
102	Placental growth factor administration prevents hypertension, increased sFltâ€1 levels and reduced glomerular filtration rate responses to placental ischemia. FASEB Journal, 2016, 30, 1214.8.	0.2	0
103	Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS ONE, 2015, 10, e0126815.	1.1	48
104	Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. International Journal of Nephrology, 2015, 2015, 1-9.	0.7	66
105	Placental Growth Factor as a Novel Marker in Uremia-Related Cardiovascular Disease. American Journal of Nephrology, 2015, 42, 115-116.	1.4	1
106	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenatal Diagnosis, 2015, 35, 386-393.	1.1	28
107	Exposure to Experimental Preeclampsia in Mice Enhances the Vascular Response to Future Injury. Hypertension, 2015, 65, 863-870.	1.3	73
108	Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney International, 2015, 87, 1201-1208.	2.6	70

#	Article	IF	Citations
109	The Effects of Parenteral Amino Acid Therapy on Protein Carbamylation in Maintenance Hemodialysis Patients. , 2015, 25, 388-392.		26
110	Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia. Hypertension, 2015, 66, 117-125.	1.3	52
111	Interferonâ€Î± and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia. Arthritis and Rheumatology, 2015, 67, 977-987.	2.9	64
112	Preeclampsia: An Old Disease with New Tools for Better Diagnosis and Risk Management. Clinical Chemistry, 2015, 61, 694-698.	1.5	16
113	Endothelial dysfunction and metabolic syndrome in preeclampsia: an alternative viewpoint. Journal of Reproductive Immunology, 2015, 108, 42-47.	0.8	47
114	24,25-Dihydroxyvitamin D3 and Vitamin D Status of Community-Dwelling Black and White Americans. Clinical Chemistry, 2015, 61, 877-884.	1.5	90
115	Pathogenesis of preeclampsia. Current Opinion in Nephrology and Hypertension, 2015, 24, 131-138.	1.0	197
116	Hydrogen sulfide. Current Opinion in Nephrology and Hypertension, 2015, 24, 170-176.	1.0	54
117	Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation, 2015, 132, 1726-1733.	1.6	111
118	Molecular Mechanisms of Preeclampsia. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a023473.	2.9	127
119	Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth. Journal of Clinical Investigation, 2015, 125, 4021-4025.	3.9	18
120	Low-Molecular Weight Heparin Increases Circulating sFlt-1 Levels and Enhances Urinary Elimination. PLoS ONE, 2014, 9, e85258.	1.1	31
121	Carbon Monoxide Prevents Hypertension and Proteinuria in an Adenovirus sFlt-1 Preeclampsia-Like Mouse Model. PLoS ONE, 2014, 9, e106502.	1.1	45
122	Ouabain inhibits placental sFlt1 production by repressing HSP27â€dependent HIFâ€1Î± pathway. FASEB Journal, 2014, 28, 4324-4334.	0.2	47
123	Response to Carbillon L et al. letter titled; â€œThe imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsiaâ€. Hypertension in Pregnancy, 2014, 33, 525-525.	0.5	1
124	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertension in Pregnancy, 2014, 33, 427-439.	0.5	38
125	Vitamin Dâ€“Binding Protein and Vitamin D in Blacks and Whites. New England Journal of Medicine, 2014, 370, 878-881.	13.9	89
126	Pre-eclampsia and cardiovascular disease. Cardiovascular Research, 2014, 101, 579-586.	1.8	170

#	Article	IF	Citations
127	Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertension in Pregnancy, 2014, 33, 250-259.	0.5	36
128	The Authors Reply. American Journal of Epidemiology, 2014, 180, 758-758.	1.6	0
129	Aldosterone Promotes Vascular Remodeling by Direct Effects on Smooth Muscle Cell Mineralocorticoid Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 355-364.	1.1	104
130	The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertension in Pregnancy, 2014, 33, 81-92.	0.5	45
131	Welles et al. Respond to "Low Vitamin D and Cardiovascular Disease". American Journal of Epidemiology, 2014, 179, 1291-1292.	1.6	0
132	Angiogenic Factors in Diagnosis, Management, and Research in Preeclampsia. Hypertension, 2014, 63, 198-202.	1.3	106
133	Protein Carbamylation in Kidney Disease: Pathogenesis and Clinical Implications. American Journal of Kidney Diseases, 2014, 64, 793-803.	2.1	97
134	Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta. American Journal of Obstetrics and Gynecology, 2014, 210, 68.e1-68.e4.	0.7	51
135	Hydrogen Sulfide Attenuates sFlt1-Induced Hypertension and Renal Damage by Upregulating Vascular Endothelial Growth Factor. Journal of the American Society of Nephrology: JASN, 2014, 25, 717-725.	3.0	95
136	Vitamin D Deficiency and Cardiovascular Events in Patients With Coronary Heart Disease: Data From the Heart and Soul Study. American Journal of Epidemiology, 2014, 179, 1279-1287.	1.6	74
137	Vitamin Dâ€“Binding Protein and Vitamin D Status of Black Americans and White Americans. New England Journal of Medicine, 2013, 369, 1991-2000.	13.9	898
138	Hydrogen peroxide-responsive copolyoxalate nanoparticles for detection and therapy of ischemiaâ€“reperfusion injury. Journal of Controlled Release, 2013, 172, 1102-1110.	4.8	72
139	VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. Journal of Heart and Lung Transplantation, 2013, 32, 120-128.	0.3	53
140	Preeclampsia Is Associated With the Presence of Transcriptionally Active Placental Fragments in the Maternal Lung. Hypertension, 2013, 62, 608-613.	1.3	39
141	Moving Forward in Sepsis Research. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1264-1265.	2.5	0
142	Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure. Science Translational Medicine, 2013, 5, 175ra29.	5.8	149
143	Response to Are Aldosterone Levels Inappropriately Low in Preeclampsia?. Hypertension, 2013, 62, e40.	1.3	0
144	Vascular Endothelial Growth Factor-A and Aldosterone. Hypertension, 2013, 61, 1111-1117.	1.3	57

#	Article	IF	Citations
145	Carbamylation of Serum Albumin and Erythropoietin Resistance in End Stage Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1927-1934.	2.2	37
146	Circulating Lymphangiogenic Factors in Preeclampsia. Hypertension in Pregnancy, 2013, 32, 42-49.	0.5	17
147	Spiral Artery Remodeling in Preeclampsia Revisited. Hypertension, 2013, 62, 1013-1014.	1.3	32
148	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertension in Pregnancy, 2013, 32, 189-201.	0.5	130
149	Conversion of Peripheral Blood NK Cells to a Decidual NK-like Phenotype by a Cocktail of Defined Factors. Journal of Immunology, 2013, 190, 3939-3948.	0.4	157
150	Transcriptional Patterns in Peritoneal Tissue of Encapsulating Peritoneal Sclerosis, a Complication of Chronic Peritoneal Dialysis. PLoS ONE, 2013, 8, e56389.	1.1	17
151	Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1135-1141.	0.7	17
152	Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L36-L46.	1.3	129
153	Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. Hypertension, 2012, 59, 256-264.	1.3	148
154	Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1447-1452.	0.7	34
155	eNOS Deficiency Acts through Endothelin to Aggravate sFlt-1â€“Induced Pre-Eclampsiaâ€“Like Phenotype. Journal of the American Society of Nephrology: JASN, 2012, 23, 652-660.	3.0	91
156	Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation, 2012, 125, 911-919.	1.6	526
157	Familial Factors in the Association between Preeclampsia and Later ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1819-1826.	2.2	35
158	Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney International, 2012, 82, 84-89.	2.6	176
159	Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure. Circulation, 2012, 125, 2728-2738.	1.6	97
160	The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia. Clinical Chemistry, 2012, 58, 837-845.	1.5	108
161	Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia. Hypertension, 2012, 60, 451-458.	1.3	84
162	Cisplatin Nephrotoxicity Involves Mitochondrial Injury with Impaired Tubular Mitochondrial Enzyme Activity. Journal of Histochemistry and Cytochemistry, 2012, 60, 521-529.	1.3	99

#	Article	IF	Citations
163	Preeclampsia and Retinopathy of Prematurity in Preterm Births. Pediatrics, 2012, 130, e101-e107.	1.0	47
164	Vasculitis Is an Antiangiogenic State. Journal of the American Society of Nephrology: JASN, 2012, 23, 8-10.	3.0	5
165	Correlation of Cystatin-C with Glomerular Filtration Rate by Inulin Clearance in Pregnancy. Hypertension in Pregnancy, 2012, 31, 22-30.	0.5	23
166	Hemodynamic, Vascular, and Reproductive Impact of FMS-Like Tyrosine Kinase 1 (FLT1) Blockade on the Uteroplacental Circulation During Normal Mouse Pregnancy1. Biology of Reproduction, 2012, 86, 57.	1.2	10
167	Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Critical Care Medicine, 2012, 40, 3034-3041.	0.4	150
168	Relaxin' with endothelial progenitor cells. Blood, 2012, 119, 326-327.	0.6	0
169	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature, 2012, 485, 333-338.	13.7	450
170	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes and Control, 2012, 23, 779-784.	0.8	18
171	Regulatory T Cells in Preeclampsia. American Journal of Pathology, 2012, 181, 1900-1902.	1.9	12
172	The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxinâ€“associated hemolytic uremic syndrome in humans and mice. Journal of Clinical Investigation, 2012, 122, 759-776.	3.9	86
173	Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia. PLoS ONE, 2012, 7, e48259.	1.1	49
174	Preeclampsia, a Disease of the Maternal Endothelium. Circulation, 2011, 123, 2856-2869.	1.6	838
175	Angiogenic Factors and Preeclampsia. Seminars in Nephrology, 2011, 31, 33-46.	0.6	374
176	Hypertension and Kidney Disease in Pregnancy: Introduction. Seminars in Nephrology, 2011, 31, 1-3.	0.6	0
177	Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nature Medicine, 2011, 17, 952-960.	15.2	750
178	Circulating angiogenic and antiangiogenic factors in women with eclampsia. American Journal of Obstetrics and Gynecology, 2011, 204, 152.e1-152.e9.	0.7	88
179	Placental expression of angiogenic factors in Trisomy 13. American Journal of Obstetrics and Gynecology, 2011, 204, 546.e1-546.e4.	0.7	18
180	Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes and Control, 2011, 22, 1587-1595.	0.8	18

#	Article	IF	Citations
181	Vitamin Dâ€“binding protein modifies the vitamin Dâ€“bone mineral density relationship. Journal of Bone and Mineral Research, 2011, 26, 1609-1616.	3.1	308
182	Early Outcomes among Those Initiating Chronic Dialysis in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2642-2649.	2.2	121
183	Angiogenic Factors in Maternal Circulation and the Risk of Severe Fetal Growth Restriction. American Journal of Epidemiology, 2011, 173, 630-639.	1.6	75
184	WT1-Dependent Sulfatase Expression Maintains the Normal Glomerular Filtration Barrier. Journal of the American Society of Nephrology: JASN, 2011, 22, 1286-1296.	3.0	58
185	Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. Circulation, 2011, 124, 940-950.	1.6	311
186	Adipose Tissue-Derived Soluble Fms-Like Tyrosine Kinase 1 Is an Obesity-Relevant Endogenous Paracrine Adipokine. Hypertension, 2011, 58, 37-42.	1.3	22
187	Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function. Journal of Cell Science, 2011, 124, 2132-2142.	1.2	13
188	Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovascular Research, 2011, 91, 632-639.	1.8	61
189	Pre-Eclampsia, Soluble Fms-Like Tyrosine Kinase 1, and the Risk of Reduced Thyroid Function: Nested Case-Control and Population Based Study. Obstetrical and Gynecological Survey, 2010, 65, 213-214.	0.2	0
190	Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. American Journal of Obstetrics and Gynecology, 2010, 202, 40.e1-40.e7.	0.7	111
191	Angiogenic dysfunction in molar pregnancy. American Journal of Obstetrics and Gynecology, 2010, 202, 184.e1-184.e5.	0.7	40
192	Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease. PLoS ONE, 2010, 5, e9246.	1.1	43
193	How Does Smoking Reduce the Risk of Preeclampsia?. Hypertension, 2010, 55, 1100-1101.	1.3	70
194	Breathing Life Into the Lifecourse Approach. Hypertension, 2010, 56, 331-334.	1.3	110
195	Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factorâ€“Signaling Inhibitors. Hypertension, 2010, 56, 1131-1136.	1.3	107
196	Leptin Exacerbates Sepsis-Mediated Morbidity and Mortality. Journal of Immunology, 2010, 185, 517-524.	0.4	63
197	First Trimester Vitamin D, Vitamin D Binding Protein, and Subsequent Preeclampsia. Hypertension, 2010, 56, 758-763.	1.3	151
198	Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy. Hypertension, 2010, 55, 1239-1245.	1.3	97

#	Article	IF	Citations
199	Placental Vasculature in Health and Disease. Seminars in Thrombosis and Hemostasis, 2010, 36, 309-320.	1.5	47
200	Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker. Seminars in Nephrology, 2010, 30, 591-601.	0.6	170
201	Pathogenesis of Preeclampsia. Annual Review of Pathology: Mechanisms of Disease, 2010, 5, 173-192.	9.6	555
202	Recombinant Vascular Endothelial Growth Factor 121 Infusion Lowers Blood Pressure and Improves Renal Function in Rats With PlacentalIschemia-Induced Hypertension. Hypertension, 2010, 55, 380-385.	1.3	150
203	First-Trimester Follistatin-Like-3 Levels in Pregnancies Complicated by Subsequent Gestational Diabetes Mellitus. Diabetes Care, 2010, 33, 664-669.	4.3	36
204	Kidney complications: Why don't statins always work?. Nature Medicine, 2010, 16, 38-40.	15.2	17
205	A complement to kidney disease: CFHR5 nephropathy. Lancet, The, 2010, 376, 748-750.	6.3	6
206	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 366-370.	0.7	50
207	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2010, 23, 1-6.	0.7	26
208	Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium. Molecular and Cellular Biology, 2009, 29, 2011-2022.	1.1	317
209	Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium. Molecular and Cellular Biology, 2009, 29, 3451-3451.	1.1	2
210	Angiogenic factor abnormalities and fetal demise in a twin pregnancy. Nature Reviews Nephrology, 2009, 5, 658-662.	4.1	16
211	Franklin H. Epsteinâ€"Researcher, Teacher, Clinician, and Humanist. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1285-1289.	2.2	2
212	Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality. Journal of the American Society of Nephrology: JASN, 2009, 20, 1140-1148.	3.0	98
213	Reactions of Peroxynitrite with Uric Acid: Formation of Reactive Intermediates, Alkylated Products and Triuret, and In Vivo Production of Triuret Under Conditions of Oxidative Stress. Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 118-149.	0.4	79
214	Klotho Variants and Chronic Hemodialysis Mortality. Journal of Bone and Mineral Research, 2009, 24, 1847-1855.	3.1	54
215	Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis. Physiology, 2009, 24, 147-158.	1.6	384
216	Hemodynamically-Directed Atenolol Therapy is Associated with a Blunted Rise in Maternal sFLTâ€“1 Levels During Pregnancy. Hypertension in Pregnancy, 2009, 28, 42-55.	0.5	15

#	Article	IF	Citations
217	Risk for developing gestational diabetes in women with twin pregnancies. Journal of Maternal-Fetal and Neonatal Medicine, 2009, 22, 293-299.	0.7	120
218	Angiogenic factors and preeclampsia. Thrombosis Research, 2009, 123, S93-S99.	0.8	59
219	Advances in the understanding of eclampsia. Current Hypertension Reports, 2008, 10, 305-312.	1.5	48
220	Targeting tumor vascular endothelium: an emerging concept for cancer therapy. Drug Development Research, 2008, 69, 340-351.	1.4	1
221	Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. American Journal of Obstetrics and Gynecology, 2008, 198, 428.e1-428.e6.	0.7	186
222	Putting pressure on pre-eclampsia. Nature Medicine, 2008, 14, 810-812.	15.2	30
223	Use of Circulating Antiangiogenic Factors to Differentiate Other Hypertensive Disorders From Preeclampsia in a Pregnant Woman on Dialysis. American Journal of Kidney Diseases, 2008, 51, 1029-1032.	2.1	25
224	Molecular mechanisms of preeclampsia. Microvascular Research, 2008, 75, 1-8.	1.1	252
225	Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochemical and Biophysical Research Communications, 2008, 371, 475-479.	1.0	26
226	Preeclampsia and Angiogenic Imbalance. Annual Review of Medicine, 2008, 59, 61-78.	5.0	283
227	A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin) Tj ETQq1 1 0.784314 rgBT /Overlock destined to develop preeclampsia and deliver a small for gestational age neonate. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 9-23.	0.7	592
228	Elevated levels of placental growth factor represent an adaptive host response in sepsis. Journal of Experimental Medicine, 2008, 205, 2623-2631.	4.2	40
229	VEGF and TGF-Î² are required for the maintenance of the choroid plexus and ependyma. Journal of Experimental Medicine, 2008, 205, 491-501.	4.2	175
230	Flt1, pregnancy, and malaria: Evolution of a complex interaction. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14243-14244.	3.3	3
231	Preeclampsia Pathogenesis. Hypertension, 2008, 51, 991-992.	1.3	40
232	Vascular endothelial growth factor decreases blood pressure in hypertensive pregnant rats. FASEB Journal, 2008, 22, 969.2.	0.2	0
233	Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. Journal of Rheumatology, 2008, 35, 631-4.	1.0	47
234	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16810-16815.	3.3	305

#	Article	IF	Citations
235	The Glomerular Injury of Preeclampsia. Journal of the American Society of Nephrology: JASN, 2007, 18, 2281-2284.	3.0	267
236	Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia. Hypertension, 2007, 50, 137-142.	1.3	271
237	Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia. Hypertension, 2007, 50, 686-692.	1.3	230
238	Pathophysiology of the Clinical Manifestations of Preeclampsia. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 543-549.	2.2	205
239	Endothelial Dysfunction. Hypertension, 2007, 49, 90-95.	1.3	227
240	Prediction of Diabetic Nephropathy Using Urine Proteomic Profiling 10 Years Prior to Development of Nephropathy. Diabetes Care, 2007, 30, 638-643.	4.3	118
241	Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia: Angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care, 2007, 30, 375-377.	4.3	23
242	Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Circulating Antiangiogenic Factors. Obstetrics and Gynecology, 2007, 109, 549-552.	1.2	58
243	Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors. Obstetrics and Gynecology, 2007, 109, 168-180.	1.2	155
244	Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. Obstetrical and Gynecological Survey, 2007, 62, 82-83.	0.2	19
245	Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Angiogenic Factors. Obstetrics and Gynecology, 2007, 109, 1206.	1.2	0
246	Activation of the orphan endothelial receptor Tie1 modifies Tie2â€mediated intracellular signaling and cell survival. FASEB Journal, 2007, 21, 3171-3183.	0.2	97
247	Placental Vasculature in Health and Disease. , 2007, , 1488-1500.		0
248	Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. Journal of Reproductive Immunology, 2007, 76, 23-29.	0.8	58
249	Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. American Journal of Obstetrics and Gynecology, 2007, 197, 176.e1-176.e6.	0.7	69
250	Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. New England Journal of Medicine, 2006, 355, 992-1005.	13.9	1,666
251	Late Postpartum Eclampsia: Examples and Review. Obstetrical and Gynecological Survey, 2006, 61, 471-480.	0.2	41
252	Circulating Angiogenic Factors and Placental Abruption. Obstetrics and Gynecology, 2006, 108, 338-344.	1.2	90

#	Article	IF	Citations
253	Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Medicine, 2006, 12, 642-649.	15.2	1,653
254	Circulating angiogenic proteins in trisomy 13. American Journal of Obstetrics and Gynecology, 2006, 194, 239-245.	0.7	68
255	Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. American Journal of Obstetrics and Gynecology, 2006, 194, 1034-1041.	0.7	101
256	Protease Activity of Urokinase and Tumor Progression in a Syngeneic Mammary Cancer Model. Journal of the National Cancer Institute, 2006, 98, 756-764.	3.0	13
257	Lipocalin 2 Antagonizes the Proangiogenic Action of Ras in Transformed Cells. Molecular Cancer Research, 2006, 4, 821-829.	1.5	29
258	Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. Journal of Experimental Medicine, 2006, 203, 1447-1458.	4.2	249
259	Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans. PLoS Medicine, 2006, 3, e46.	3.9	440
260	Circulating Angiogenic Factors in Preeclampsia. Clinical Obstetrics and Gynecology, 2005, 48, 372-386.	0.6	131
261	Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. American Journal of Obstetrics and Gynecology, 2005, 193, 16-22.	0.7	115
262	Preeclampsia: A renal perspective. Kidney International, 2005, 67, 2101-2113.	2.6	250
263	Role of elongin-binding domain of von hippel lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene, 2005, 24, 7850-7858.	2.6	51
264	Is loss of podocyte foot processes necessary for the induction of proteinuria?. American Journal of Kidney Diseases, 2005, 45, 436.	2.1	10
265	Extra-placental Expression of Vascular Endothelial Growth Factor Receptor-1, (Flt-1) and Soluble Flt-1 (sFlt-1), by Peripheral Blood Mononuclear Cells (PBMCs) in Normotensive and Preeclamptic Pregnant Women. Placenta, 2005, 26, 563-573.	0.7	175
266	Lipocalin 2 Diminishes Invasiveness and Metastasis of Ras-transformed Cells. Journal of Biological Chemistry, 2005, 280, 13641-13647.	1.6	107
267	Hypertension During Pregnancy. Hypertension, 2005, 46, 1250-1251.	1.3	28
268	Urinary Placental Growth Factor and Risk of Preeclampsia. JAMA - Journal of the American Medical Association, 2005, 293, 77.	3.8	307
269	Vascular Endothelial Growth Factor Induces Branching Morphogenesis/Tubulogenesis in Renal Epithelial Cells in a Neuropilin-Dependent Fashion. Molecular and Cellular Biology, 2005, 25, 7441-7448.	1.1	54
270	Uric acid and preeclampsia. Seminars in Nephrology, 2005, 25, 56-60.	0.6	74

#	Article	IF	Citations
271	Circulating Angiogenic Factors in the Pathogenesis and Prediction of Preeclampsia. Hypertension, 2005, 46, 1077-1085.	1.3	342
272	Soluble Fms-like Tyrosine Kinase 1 and Endothelial Dysfunction in the Pathogenesis of Preeclampsia. Pediatric Research, 2005, 57, 1R-7R.	1.1	217
273	Angiogenic Factors in the Pathogenesis of Preeclampsia. Current Topics in Developmental Biology, 2005, 71, 297-312.	1.0	65
274	Insulin Resistance and Alterations in Angiogenesis. Hypertension, 2004, 43, 988-992.	1.3	93
275	Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6239-6243.	1.8	190
276	Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney International, 2004, 66, 281-287.	2.6	201
277	Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes. Kidney International, 2004, 66, 1471-1478.	2.6	19
278	First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 770-775.	1.8	395
279	New Aspects in the Pathophysiology of Preeclampsia. Journal of the American Society of Nephrology: JASN, 2004, 15, 2440-2448.	3.0	161
280	Circulating Angiogenic Factors and the Risk of Preeclampsia. New England Journal of Medicine, 2004, 350, 672-683.	13.9	3,158
281	Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Seminars in Nephrology, 2004, 24, 548-556.	0.6	45
282	Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 2003, 111, 649-658.	3.9	3,356
283	Endostatin is a potential inhibitor of Wnt signaling. Journal of Cell Biology, 2002, 158, 529-539.	2.3	141
284	Renal cancer: molecular mechanisms and newer therapeutic options. Current Opinion in Nephrology and Hypertension, 2002, 11, 37-42.	1.0	81
285	Endostatin Causes G1 Arrest of Endothelial Cells through Inhibition of Cyclin D1. Journal of Biological Chemistry, 2002, 277, 16464-16469.	1.6	197
286	VHL tumor suppressor regulates Cl^{â^'}/HCO₃^{â^'}exchange and Na⁺/H⁺exchange activities in renal carcinoma cells. Physiological Genomics, 2001, 5, 119-128.	1.0	40